Ascend Biopharmaceuticals Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 1
- Market Cap
- -
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
Phase 2
Completed
- Conditions
- Basal Cell Nevus SyndromeBasal Cell Carcinoma
- Interventions
- Biological: ASN-002
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT04416516
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Burswood Dermatology, Perth, Western Australia, Australia
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Phase 1
Suspended
- Conditions
- Basal Cell Carcinoma in Basal Cell Nevus Syndrome
- Interventions
- Biological: ASN-002
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03208296
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Phase 1
Completed
- Conditions
- Skin NeoplasmNodular Basal Cell Carcinoma of SkinBasal Cell Nevus Syndrome
- Interventions
- Biological: ASN-002
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT02550678
- Locations
- 🇦🇺
St George Dermatology and Skin Cancer Centre, Kogarah, New South Wales, Australia
🇦🇺Siller Medical T/A Central Brisbane Dermatology, Brisbane, Queensland, Australia
🇦🇺Veracity Clinical Research, Brisbane, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath